München (ots) - Ab sofort verstärken Christiane Ritter, Tim Jungblut und Sebastian Schütze das Team von ...
Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test
Lake Zurich, Illinois (ots/PRNewswire) -
Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today it has signed a five-year exclusive worldwide agreement with Verax Biomedical Incorporated to market, sell and distribute Verax's unique PanGenera(R) Detection (PGD) technology, a rapid diagnostic test used to detect bacterial contaminants in donated blood platelets.
The Verax PGD(R) test is the only rapid test for the detection of bacteria cleared by the United States Food and Drug Administration (FDA) and CE Marked in Europe. Development is underway to apply the Verax PGD(R) technology to detect bacteria in other blood components, tissues for transplantation and cell-based therapies.
The Verax PGD(R) test, based on proprietary technology developed by Verax, consists of an easy-to-use disposable handheld device and reagents that work together to detect the presence of bacterial contaminants in platelets. The test can be performed in fewer than 30 minutes and is designed for use in hospitals, cancer centers and other sites of care as a safeguard immediately prior to transfusion.
More than 5 million platelet doses are transfused annually worldwide. Platelets are tiny cells in blood that help blood clot. They are transfused when platelets levels are low - as, for example, a result of illness or the side effect of some chemotherapy treatments.
An estimated one in 2,000 to 3,000 platelet units may contain bacteria, and up to 50 percent of bacteria-contaminated platelets may escape detection by conventional culture testing, according to experts.(i) Bacteria can cause fatal reactions, especially in immune-compromised patients. The Verax PGD(R) test, a rapid immunoassay, targets antigens found on the surface of a wide spectrum of common bacteria known to be pathogenic to humans in high concentrations.
"Bacterial contamination in platelets is a serious concern in transfusion medicine," said Darrell J. Triulzi, M.D., medical director of the Institute for Transfusion Medicine and the University of Pittsburgh Medical Center's Division of Transfusion Medicine, which is using the Verax PGD(R) test. "The blood center community has made progress with the implementation of culture-based tests, but these occur at the point of collection when bacteria levels can be too low for detection. A rapid, point-of-care assay, such as the Verax PGD(R) test, takes place just prior to transfusion, which is the best time to detect bacteria levels in platelets and provides a more comprehensive strategy for patient safety."
"Transfusion safety is central to the mission of Fenwal and our customers," said Ron K. Labrum, Fenwal president and chief executive officer. "This agreement is another example of how Fenwal is bringing advanced technology, ideas and performance to our vital industry."
"Fenwal is a pioneer in the development of products that improve blood safety worldwide," said Jim Lousararian, Verax president and chief executive officer. "We are confident that with Fenwal's support we can increase adoption of the Verax PGD(R) test and improve health-care outcomes by reducing transfusion-related issues associated with bacterial contamination."
About Verax Biomedical
Verax Biomedical Inc. is a leading developer of rapid tests for detecting bacterial contaminants in blood cells and tissue. The privately held company was founded in 1999. Its headquarters and laboratory facilities are in Worcester, Massachusetts. The Verax PGD(R) test is currently cleared by the FDA as a rapid, qualitative immunoassay for the detection of bacteria in leukocyte-reduced apheresis platelets as an adjunct quality-control test following previous bacterial testing. For more information, visit www.veraxbiomedical.com.
Fenwal Inc. is a global medical technology company focused on improving blood collection, separation, safety and availability for patient care. Fenwal became an independent company in 2007, but its roots go back to 1949 with the founding of Fenwal Laboratories. Fenwal developed the first flexible, disposable container for blood collection, eliminating complications associated with glass containers and allowing blood to be separated into therapeutic components. Today, the company's products and advanced collection and separation technologies are used throughout the world to help ensure a safe and available supply of lifesaving blood and blood products. Fenwal Inc. is based in Lake Zurich, Illinois. For more information, please visit www.fenwalinc.com.
(i.) Benjamin R. and Wagner S. The residual risk of sepsis: modeling the effect of concentration on bacterial detection in 2-bottle culture systems and estimation of false-negative culture rates. Transfusion 2007; 47:1381-1389.
ots Originaltext: Fenwal Inc.
Im Internet recherchierbar: http://www.presseportal.ch
Geoffrey Fenton of Fenwal Inc., +1-847-550-2321,